

9th European CAR T-cell Meeting

Abstract / case submission guidelines

Introduction

The abstract submission guidelines of the 9th European CAR T-cell Meeting are intended to provide clear instructions before submitting an abstract. **You are kindly requested to carefully read the guidelines stated below.**

The EHA/EBMT and the Scientific Program Committee (SPC) of the meeting maintain the right to reject any abstract and clinical case submission that does not meet the requirements below.

Table of Contents

Key Dates	2
Abstract and clinical case submission	3
1. Terms and conditions	3
2. Submission guidelines	3
3. Topics	5
4. Submission specifications	6
5. Review, selection and publication	6
6. Applicable Law and Jurisdiction	6
7. Travel Grant Application Guidelines	7

Key Dates

Date	Item
July 1, 2026	Abstract / case submission open
November 14, 2026 (23:59 CEST)	Abstract / case submission deadline
By December 1, 2026	Notification to abstract submitters
December 15, 2026	Abstract / case withdrawal deadline

Abstract and clinical case submission

1. Terms and conditions

- 1) The Scientific Program Committee (SPC) encourages the submission of original scientific material unpublished at the time of the abstract/clinical submission deadline:
 - I. Abstracts submitted to regional or national hematology meetings can be submitted to the meeting for inclusion in the program;
 - II. Abstracts submitted to large international meetings which are organized in the same period as the meeting (January - March 2027) are allowed to be submitted to the meeting.;
 - III. Abstracts/clinical cases submitted to other large international meetings may also be submitted providing a clear indication about significant novel or updated information included in the appropriate abstract submission field.
- 2) Authors of submitted abstracts shall be the sole and exclusive owner of the abstract and all associated intellectual property rights. By submitting the abstract to EHA, the author grants EHA the right to use and (commercial) reprint the abstract in relation to the Scientific Meeting. Authors of submitted abstracts understand and agree that EHA will not pay compensation for this license.
- 3) Authors of submitted abstracts guarantee that the abstract (and all associated intellectual property rights) is free of any third-party rights to the fullest extent permitted by law, including but not limited to, inventor's rights of remuneration and any other ancillary rights.
- 4) By submitting an abstract, the submitting author confirms that they have approval from all the co-authors to submit and use the data in the abstract.
- 5) Submitted abstracts are considered embargoed from the time of submission. The embargo is lifted at the start of the meeting.
- 6) Please do not submit the same study in multiple abstracts/clinical cases. Abstracts/clinical cases that appear as more than one version of a single study will be rejected.
- 7) Similarly, abstracts/clinical cases or (close) copies, may not be submitted under more than 1 (one) topic.
- 8)

2. Submission guidelines

The submitted abstracts / clinical cases should fully adhere to the guidelines below.

- 1) Abstracts / clinical cases should be submitted in clear (American) English to allow the reviewers to focus on the scientific content of the abstract/clinical case. Non-English-speaking authors are encouraged to have their abstract/clinical case checked for grammar and spelling.
- 2) The SPC assumes all presenting authors have proficiency in English, thus are able to present and respond to questions.
- 3) In clinical studies, please state whether informed consent was obtained.
- 4) The title and text may not contain trade names.
- 5) If off label use of drugs was involved, please state this clearly.
- 6) Withdrawal policy: If authors wish to withdraw their abstracts/clinical cases from presentation or publication, they are requested to confirm with the EHA Executive Office before **December 15, 2026 (23:59 CET)**. Consequently, the abstract/clinical case will not be presented nor published.

3. Topics

Please select the most appropriate topic during the abstract and case submission:

CAR-based Cellular Therapy - Clinical

- Biomarkers for CAR T efficacy and prediction model for response and toxicity
- Challenges of CAR-based cellular therapy (bridging therapies and lymphodepletion), and clinical indication
- Clinical investigations into therapeutic applications of CAR-T cell in oncology and other fields, adult/pediatric indications
- Management of toxicities (early and late)

CAR-based Cellular Therapy - Preclinical

- CAR T cell manufacturing methodologies
- Innovative T cell engineering, CAR designs, and optimization of CAR T cell function
- Mechanistic studies of CAR T efficacy and toxicities, and tumor resistance
- Novel in vivo and in vitro models to functionally evaluate CAR T cells

Clinical cases

- Clinical case on multiple myeloma
- Clinical case on new technologies for CAR T development
- Clinical case on solid tumors

Other

- Access to CAR T
- Advanced Practice Roles within the Multidisciplinary team in CAR T Therapy
- Models of Care and Multidisciplinary Collaboration in CAR T Programs
- Perspectives in Adolescent and Young Adult (AYA) CAR T Care
- Quality of Life
- Real-world Nursing Practice in CAR T-cell Therapy
- Symptom Management and Toxicity Monitoring in CAR T Patients

4. Submission specifications

- 1) Title count: max. 300 characters incl. space.
- 2) Character limit: 3500 characters (incl. spaces & punctuation and headers in the template).
- 3) Please use the following subheadings: Background / Aims / Methods / Results / Summary - Conclusion
- 4) Images have to be submitted as JPEG, tif, or gif files:
 - I. Due to limited space, only a simple graph/image can be submitted;
 - II. Images and graphs should reproduce well in black and white;
 - III. Image file should not exceed 500KB.
- 5) Authors: There is no limit to the number of authors.
- 6) References are obligatory when submitting an abstract or clinical case.

5. Review, selection and publication

- 1) All submitted abstracts/clinical cases will be reviewed by the Scientific Program Committee of the 9th European CAR T-cell Meeting.
- 2) Abstracts/clinical cases may be selected for
 - oral presentation
 - poster presentation
 - rejection
- 3) Only the submitting author will receive a notification letter of acceptance for oral presentation, oral flash talk, or a notice of rejection, by email by **December 1, 2026**.
- 4) Authors of abstracts selected for an oral presentation or poster presentation will be informed about the date of the session, and presentation guidelines will be provided.
- 5) Oral and poster presenters will need to register themselves in order to present their abstracts in the Scientific Meeting.

6. Applicable Law and Jurisdiction

The above Terms and conditions are governed by the laws of the Netherlands. Any dispute related to these terms and conditions and the use or publication of the abstract shall be exclusively submitted to the District Court in The Hague, The Netherlands.

7. Travel Grant Application Guidelines

Key Dates

Date	Item
July 1, 2026	Travel grant application open
November 14, 2026 (23:59 CEST)	Travel grant application deadline
By December 1, 2026	Notification to selected travel grants applicants
December 15, 2026	Travel grant acceptance deadline

1. Eligibility criteria:

- The applicant is 40 years of age or younger at the time of travel grant application.
- The applicant is an EHA and/or EBMT member or has applied for a membership by November 14, 2026.
- The 2026 membership fee has been paid by November 14, 2026.

2. Application Process:

- Interested individuals can submit their application for the travel grant simultaneously with their abstract submission..

3. Selection:

- Only applications that meet the eligibility criteria will be considered.
- Applications with an accepted abstracts as an oral or poster presentation will be considered.
- There are a limited number of travel grants available.

4. Travel Grant Coverage:

- Complimentary registration arranged by EHA/EBMT for on-site attendance;
- Maximum of € 500 for travel arrangements;
- A reimbursement form must be completed (after the meeting), and the grant amount will be transferred after the meeting based on the attendance obligations (see point 5).

5. Obligations of Grant Recipients:

- Grant recipients must confirm their acceptance by **December 15, 2026**, and provide any necessary documentation to facilitate the arrangements.
- Grant recipients must attend the full scientific meeting (sign-in will be required at the beginning of each day).

- Please note that the grant is non-transferable to other persons or meetings/congresses.
- Travel grant recipients must make their own travel arrangements (i.e. flight/train, hotel accommodation, etc.).

6. Deadline:

- The deadline for travel grant application is **November 14, 2026 (23:59 CET)**.

7. Notification:

- Applicants will be notified of their travel grant status by **December 1, 2026** together with the abstract notification letter.

Any questions regarding the criteria, the application, or the procedure can be directed to travelgrants@ehaweb.org.